Predicting poor vaccine responders to Hepatitis B vaccination

Brief description of study

Hepatitis B vaccines are indicated broadly for the prevention of hepatitis B infection, yet the vaccine is not uniformly effective in all individuals. We need better understanding of the relevant T and B immunology of the vaccine response to understand why some people respond better than others. Recently, an adjuvanted hepatitis B vaccine was approved that leads to better immune responses with fewer doses. Here, we seek to understand 1) what is the immunological difference between vaccine responders and nonresponders, and 2) what is the difference in the immune responses generated by the adjuvanted vaccine and with the nonadjuvanted vaccine? By focusing on the T and B cell responses in peripheral blood, we will study the generation, maintenance, and longevity of the immune response in those who respond well versus those who do not respond well.


Clinical Study Identifier: s20-01782
ClinicalTrials.gov Identifier: NCT04674462


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.